Hepatocellular Carcinoma News and Research

RSS
CIP2A pathway involved in erlotinib response

CIP2A pathway involved in erlotinib response

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

Can-Fite's CF102 drug gets approval in Israel for patient with hepatocellular carcinoma

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

CASI's ENMD-2076 gets FDA Orphan Drug designation for HCC treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Bayer announces Health Canada approval of Nexavar for differentiated thyroid cancer treatment

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Drug everolimus fails to improve overall survival in advanced liver cancer patients

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Alcoholic liver disease: an interview with Dr Vinood Patel, University of Westminster

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Antiviral therapy may prevent hepatitis B virus from developing into hepatocellular carcinoma

Antiviral therapy may prevent hepatitis B virus from developing into hepatocellular carcinoma

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Provectus’ shares to begin trading on NYSE MKT on  May 16, 2014

Provectus’ shares to begin trading on NYSE MKT on May 16, 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma on the rise among Mexican Americans

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule reports net loss of $7,141,000 in first quarter 2014

Liver cancer screening in cirrhosis patients improves survival rates

Liver cancer screening in cirrhosis patients improves survival rates

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

Symposium focused on Surefire Medical's COSY clinical trial to be held at ECIO meeting

New data focuses on different approaches to improve diagnosis and treatment of HCC

New data focuses on different approaches to improve diagnosis and treatment of HCC

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.